CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update May 16, 2022 8:05am EDT
CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Apr 28, 2022 8:35am EDT
CNS Pharmaceuticals to Participate in the Virtual Investor Glioblastoma Multiforme (GBM) Spotlight Event Apr 12, 2022 8:35am EDT
CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Apr 06, 2022 8:35am EDT
CNS Pharmaceuticals Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Apr 05, 2022 8:35am EDT
CNS Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest Mar 23, 2022 8:35am EDT
CNS Pharmaceuticals Reiterates Operational Progress and Addresses Recent Share Price Activity in Video to Shareholders Mar 09, 2022 9:20am EST
CNS Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update Mar 03, 2022 8:35am EST
CNS Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference Jan 20, 2022 8:45am EST
CNS Pharmaceuticals Announces Closing of $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules Jan 10, 2022 5:00pm EST
